<p>在生物技术这个繁忙的世界中，创新仍然是增长的基石。一些以开创性研究和快速适应健康挑战而闻名的生物技术股票，特别有望在未来表现出色。</p>
<p>全球生物技术市场在 2023 年达到 1.54 万亿美元，预计到 2033 年将飙升至 5.68 万亿美元。这一增长预计将受到多种因素的推动，包括强劲的政府支持、监管框架的进步以及个性化药物和孤儿药物配方的日益流行。</p>
<p>随着全球卫生重点的转变和对先进治疗需求的增加，那些深度参与开发新兴健康问题和慢性疾病治疗的生物技术公司引起了相当大的关注。此外，美国食品药品监督管理局对关键药物的快速批准流程进一步突出了那些准备迅速增长的公司。</p>
<p>随着我们逼近 2024 年夏季中期，以下是三家有望实现强劲增长的生物技术股票。每家公司不仅展示了强大的基本面和创新管道，而且承诺改变未来的医疗格局，使它们成为任何投资组合的首选候选股。</p>
<h2>安进（AMGN）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>来源：Shutterstock</p>
<p><strong>安进</strong>（纳斯达克：<strong>AMGN</strong>）是生物技术行业中的一家强大参与者。该公司强劲的财务状况、强大的产品管道和战略市场定位使其在生物技术行业中脱颖而出。</p>
<p>过去一年，安进的股价上涨超过 42%。该公司在 2024 年第一季度的业绩中突显了其强劲的财务基础，报告的非通用会计原则每股收益为 3.96 美元，超过了华尔街的预期。营收也实现了可观增长，报告的营收为 745 亿美元，同比增长 22%。安进对 2024 财年的指导也提振了投资者信心，预计营运每股收益在 19 至 20.20 美元之间。</p>
<p>安进的创新管道仍然充满活力，特别是在减重和肿瘤领域。该公司在 GLP-1 减重药物，特别是 MariTide 药物的持续开发中，展现出与 <strong>Eli Lilly</strong> 的 Wegovy 和 <strong>Novo Nordisk</strong> 的 Ozempic 等当前市场领导者具有竞争潜力。MariTide 的早期研究显示出有希望的结果，表明在肥胖管理方面具有差异化的潜力，可以满足重大未满足的医疗需求。</p>
<p>此外，安进的肿瘤组合继续扩大，关键药物如 Blincyto 和 Repatha 表现出色。特别是 Blincyto 仅在 2024 年第一季度就创造了 2.24 亿美元的销售额，同比增长 25.8%，突显了其日益增长的采用率和市场渗透率。</p>
<h2>吉利德科学（GILD）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>来源：Sundry Photography / Shutterstock.com</p>
<p><strong>吉利德科学</strong>（纳斯达克：<strong>GILD</strong>）拥有多样化的资产组合和强大的研发能力，可能会回报生物技术领域的长期投资者。</p>
<p>该公司继续主导艾滋病毒市场，这一领域仍然是其财务支柱。特别是美国市场具有强大的定价权，对其营收贡献巨大。该公司领先的艾滋病毒药物 Biktarvy 和 Descovy 保持着强劲的销售增长，其中 Biktarvy 占据了 49% 的市场份额，Descovy 超过 40%。</p>
<p>吉利德正在为一个由创新和平衡组合增长定义的未来定位自己。该公司的研发战略旨在推动其传统艾滋病毒强项之外的强大管道。这包括在肿瘤学和其他治疗领域取得有希望的进展，吉利德可以利用其研究实力推动长期股东回报。</p>
<p>该公司的股价相对于其历史倍数和行业中位数交易存在折价，主要是由于最近的业绩波动。然而，对于长期投资者而言，这可能代表一个引人注目的入场点，考虑到吉利德的强大基本面和超过 4% 的高股息率。</p>
<h2>福泰制药（VRTX）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>来源：Pavel Kapysh / Shutterstock.com</p>
<p><strong>福泰制药</strong>（纳斯达克：<strong>VRTX</strong>）以其在治疗囊性纤维化（<strong>CF</strong>）等生命威胁性遗传疾病方面的创新药物开发方法脱颖而出。</p>
<p>截至 2024 年第一季度，福泰制药的营收达到了 269 亿美元，比去年同期增长了 13%。这一强劲增长主要是由公司的 Trikafta/Kaftrio 等 CF 治疗药物推动的。这些治疗药物已经覆盖了北美、欧洲和澳大利亚近三分之二的 92,000 名 CF 患者，展示了公司对目标市场的深度渗透。</p>
<p>公司对现有 CF 药物的战略扩张和标签增强继续拓宽其市场范围。此外，福泰制药强大的管道，包括潜在的用于疼痛、β-地中海贫血、镰状细胞病和 1 型糖尿病的治疗药物，承诺维持其增长轨迹。</p>
<p>最近批准和商业推出的 CASGEVY，一种用于镰状细胞病和β-地中海贫血的 CRISPR 基因编辑疗法，突显了福泰制药进军基因编辑领域的努力，强调了其对尖端技术的承诺。</p>
<p><em>在发布日期，Mohammed Saqib 没有持有（直接或间接）本文提到的证券中的任何头寸。</em> <em>本文中表达的观点属于作者个人，受到 InvestorPlace.com 的</em> <em>发布准则</em> <em>约束。</em></p>
<p><em>在发布日期，负责编辑没有持有（直接或间接）本文提到的证券中的任何头寸。</em></p>
<p>Mohammed Saqib 是一位具有股票研究和财务建模经验的研究分析师。他广泛涵盖科技行业上市股票，以基本分析作为其方法的核心。目前正在攻读金融硕士学位，Saqib 致力于获得 CFA 牌照，以进一步增进他在这一领域的专业知识。</p>

吉利德科学

安进

福泰制药

<p>全球生物科技市场预计未来几年将显著增长，受政府支持和监管框架进展等因素推动。三家具备强劲增长潜力的生物科技股票包括安进、吉利德科学和福泰制药。安进拥有强劲的财务实力和创新的产品线，吉利德科学主导 HIV 市场并拥有多样化的资产组合。福泰制药以其创新治疗囊性纤维化的方法脱颖而出。这些股票为长期投资者提供潜在机会</p>

<p>In the bustling world of biotechnology, innovation remains the cornerstone of growth. Some biotech stocks, known for their groundbreaking research and rapid adaptation to health challenges, are particularly well-positioned to do well in the future.</p>
<div class="lb-trans"><p>在生物技术这个繁忙的世界中，创新仍然是增长的基石。一些以开创性研究和快速适应健康挑战而闻名的生物技术股票，特别有望在未来表现出色。</p>
</div><p>The global biotechnology market, valued at $1.54 trillion in 2023, is expected to soar to $5.68 trillion by 2033. This growth is expected to be fueled by various factors, including strong government support, advancements in regulatory frameworks, and the rising popularity of personalized medicine and orphan drug formulations.</p>
<div class="lb-trans"><p>全球生物技术市场在 2023 年达到 1.54 万亿美元，预计到 2033 年将飙升至 5.68 万亿美元。这一增长预计将受到多种因素的推动，包括强劲的政府支持、监管框架的进步以及个性化药物和孤儿药物配方的日益流行。</p>
</div><p>As global health priorities shift and the demand for advanced therapeutics increases, biotech companies that are deeply involved in developing treatments for emerging health issues and chronic diseases are drawing considerable attention. Additionally, the FDA’s expedited approval process for critical drugs has further spotlighted companies poised for rapid growth.</p>
<div class="lb-trans"><p>随着全球卫生重点的转变和对先进治疗需求的增加，那些深度参与开发新兴健康问题和慢性疾病治疗的生物技术公司引起了相当大的关注。此外，美国食品药品监督管理局对关键药物的快速批准流程进一步突出了那些准备迅速增长的公司。</p>
</div><p>As we approach the middle of Summer 2024, here are three biotech stocks that are poised for robust growth. Each company not only demonstrates strong fundamentals and innovative pipelines but also holds the promise of transforming future healthcare landscapes, making them prime candidates for any investment portfolio.</p>
<div class="lb-trans"><p>随着我们逼近 2024 年夏季中期，以下是三家有望实现强劲增长的生物技术股票。每家公司不仅展示了强大的基本面和创新管道，而且承诺改变未来的医疗格局，使它们成为任何投资组合的首选候选股。</p>
</div><h2>Amgen (AMGN)</h2>
<div class="lb-trans"><h2>安进（AMGN）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Shutterstock</p>
<div class="lb-trans"><p>来源：Shutterstock</p>
</div><p><strong>Amgen</strong> (NASDAQ: <strong>AMGN</strong>) stands as a formidable player in the biotech industry. The company’s strong financials, robust product pipeline, and strategic market positioning make it a standout in the biotech industry.</p>
<div class="lb-trans"><p><strong>安进</strong>（纳斯达克：<strong>AMGN</strong>）是生物技术行业中的一家强大参与者。该公司强劲的财务状况、强大的产品管道和战略市场定位使其在生物技术行业中脱颖而出。</p>
</div><p>In the past year, Amgen has seen its stock price increase by over 42%. The company’s strong financial footing was highlighted in its Q1 2024 results, where it reported non-GAAP EPS of $3.96, surpassing Wall Street expectations. Revenue also saw a commendable increase, with $7.45 billion reported, marking a 22% YoY (year-over-year). Amgen’s guidance for fiscal year 2024 has also boosted investor confidence, projecting operating EPS between $19 and $20.20.</p>
<div class="lb-trans"><p>过去一年，安进的股价上涨超过 42%。该公司在 2024 年第一季度的业绩中突显了其强劲的财务基础，报告的非通用会计原则每股收益为 3.96 美元，超过了华尔街的预期。营收也实现了可观增长，报告的营收为 745 亿美元，同比增长 22%。安进对 2024 财年的指导也提振了投资者信心，预计营运每股收益在 19 至 20.20 美元之间。</p>
</div><p>Amgen’s innovation pipeline remains vigorous, particularly in the weight-loss and oncology segments. The company’s ongoing developments in GLP-1 weight loss drugs, specifically the MariTide medication, demonstrate significant potential to rival current market leaders like <strong>Eli Lilly’s</strong> Wegovy and <strong>Novo Nordisk’s</strong> Ozempic. Early phase studies of MariTide show promising results, indicating efficacy in obesity management with a differentiated profile that could meet significant unmet medical needs.</p>
<div class="lb-trans"><p>安进的创新管道仍然充满活力，特别是在减重和肿瘤领域。该公司在 GLP-1 减重药物，特别是 MariTide 药物的持续开发中，展现出与 <strong>Eli Lilly</strong> 的 Wegovy 和 <strong>Novo Nordisk</strong> 的 Ozempic 等当前市场领导者具有竞争潜力。MariTide 的早期研究显示出有希望的结果，表明在肥胖管理方面具有差异化的潜力，可以满足重大未满足的医疗需求。</p>
</div><p>Additionally, Amgen’s oncology portfolio continues to expand with key drugs like Blincyto and Repatha, which are showing solid sales performance. Blincyto, in particular, generated $224 million in the first quarter of 2024 alone, up 25.8% year-over-year, highlighting its increasing adoption and market penetration.</p>
<div class="lb-trans"><p>此外，安进的肿瘤组合继续扩大，关键药物如 Blincyto 和 Repatha 表现出色。特别是 Blincyto 仅在 2024 年第一季度就创造了 2.24 亿美元的销售额，同比增长 25.8%，突显了其日益增长的采用率和市场渗透率。</p>
</div><h2>Gilead Sciences (GILD)</h2>
<div class="lb-trans"><h2>吉利德科学（GILD）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Sundry Photography / Shutterstock.com</p>
<div class="lb-trans"><p>来源：Sundry Photography / Shutterstock.com</p>
</div><p><strong>Gilead Sciences</strong> (NASDAQ: <strong>GILD</strong>) boosts a diverse asset portfolio and strong R&amp;D capabilities that could reward long-term investors in the biotech space.</p>
<div class="lb-trans"><p><strong>吉利德科学</strong>（纳斯达克：<strong>GILD</strong>）拥有多样化的资产组合和强大的研发能力，可能会回报生物技术领域的长期投资者。</p>
</div><p>The company continues to dominate the HIV market, a segment that remains its financial backbone. The U.S. market, in particular, offers strong pricing power, contributing significantly to its revenue stream. The company’s leading HIV medications, Biktarvy and Descovy, have maintained robust sales growth, with Biktarvy achieving a 49% market share and Descovy over 40%.</p>
<div class="lb-trans"><p>该公司继续主导艾滋病毒市场，这一领域仍然是其财务支柱。特别是美国市场具有强大的定价权，对其营收贡献巨大。该公司领先的艾滋病毒药物 Biktarvy 和 Descovy 保持着强劲的销售增长，其中 Biktarvy 占据了 49% 的市场份额，Descovy 超过 40%。</p>
</div><p>Gilead is positioning itself for a future defined by innovation and balanced portfolio growth. The company’s R&amp;D strategy is geared towards advancing a robust pipeline outside of its traditional HIV stronghold. This includes promising developments in oncology and other therapeutic areas where Gilead can leverage its research prowess to drive long-term shareholder returns.</p>
<div class="lb-trans"><p>吉利德正在为一个由创新和平衡组合增长定义的未来定位自己。该公司的研发战略旨在推动其传统艾滋病毒强项之外的强大管道。这包括在肿瘤学和其他治疗领域取得有希望的进展，吉利德可以利用其研究实力推动长期股东回报。</p>
</div><p>The company’s stock trades at a discount relative to its historical multiples and sector median, primarily due to recent performance hiccups. However, for long-term investors, this could represent a compelling entry point, given Gilead’s strong fundamentals and high dividend yield, which exceeds 4%.</p>
<div class="lb-trans"><p>该公司的股价相对于其历史倍数和行业中位数交易存在折价，主要是由于最近的业绩波动。然而，对于长期投资者而言，这可能代表一个引人注目的入场点，考虑到吉利德的强大基本面和超过 4% 的高股息率。</p>
</div><h2>Vertex Pharmaceuticals (VRTX)</h2>
<div class="lb-trans"><h2>福泰制药（VRTX）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Pavel Kapysh / Shutterstock.com</p>
<div class="lb-trans"><p>来源：Pavel Kapysh / Shutterstock.com</p>
</div><p><strong>Vertex Pharmaceuticals</strong> (NASDAQ: <strong>VRTX</strong>) stands out for its innovative approach to drug development, particularly in treating cystic fibrosis ( <strong>CF</strong>), a life-threatening genetic disease.</p>
<div class="lb-trans"><p><strong>福泰制药</strong>（纳斯达克：<strong>VRTX</strong>）以其在治疗囊性纤维化（<strong>CF</strong>）等生命威胁性遗传疾病方面的创新药物开发方法脱颖而出。</p>
</div><p>As of Q1 2024, Vertex posted revenues of $2.69 billion, up 13% from the same period last year. The robust growth was driven predominantly by the company’s CF treatments like Trikafta/Kaftrio. These treatments have reached nearly three-quarters of the 92,000 CF patients in North America, Europe, and Australia, showcasing the company’s deep penetration into its target market.</p>
<div class="lb-trans"><p>截至 2024 年第一季度，福泰制药的营收达到了 269 亿美元，比去年同期增长了 13%。这一强劲增长主要是由公司的 Trikafta/Kaftrio 等 CF 治疗药物推动的。这些治疗药物已经覆盖了北美、欧洲和澳大利亚近三分之二的 92,000 名 CF 患者，展示了公司对目标市场的深度渗透。</p>
</div><p>The company’s strategic expansions and label enhancements for its existing CF drugs continue to broaden its market scope. Furthermore, Vertex’s strong pipeline, which includes potential treatments for pain, beta-thalassemia, sickle cell disease, and type 1 diabetes, promises to sustain its growth trajectory.</p>
<div class="lb-trans"><p>公司对现有 CF 药物的战略扩张和标签增强继续拓宽其市场范围。此外，福泰制药强大的管道，包括潜在的用于疼痛、β-地中海贫血、镰状细胞病和 1 型糖尿病的治疗药物，承诺维持其增长轨迹。</p>
</div><p>The recent approval and commercial rollout of CASGEVY, a CRISPR-based therapy for sickle cell disease and beta-thalassemia, highlight Vertex’s foray into gene editing, underscoring its commitment to cutting-edge technology.</p>
<div class="lb-trans"><p>最近批准和商业推出的 CASGEVY，一种用于镰状细胞病和β-地中海贫血的 CRISPR 基因编辑疗法，突显了福泰制药进军基因编辑领域的努力，强调了其对尖端技术的承诺。</p>
</div><p><em>On the date of publication, Mohammed Saqib did not hold (either directly or indirectly) any positions in the securities mentioned in this article.</em> <em>The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com</em> <em>Publishing Guidelines</em> <em>.</em></p>
<div class="lb-trans"><p><em>在发布日期，Mohammed Saqib 没有持有（直接或间接）本文提到的证券中的任何头寸。</em> <em>本文中表达的观点属于作者个人，受到 InvestorPlace.com 的</em> <em>发布准则</em> <em>约束。</em></p>
</div><p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div class="lb-trans"><p><em>在发布日期，负责编辑没有持有（直接或间接）本文提到的证券中的任何头寸。</em></p>
</div><p>Mohammed Saqib is a research analyst with experience in equity research and financial modeling. He has extensively covered stocks listed in the tech sector using fundamental analysis as the cornerstone of his approach. Currently pursuing a master’s degree in finance, Saqib is dedicated to obtaining the CFA charter to augment his expertise in the field further.</p>
<div class="lb-trans"><p>Mohammed Saqib 是一位具有股票研究和财务建模经验的研究分析师。他广泛涵盖科技行业上市股票，以基本分析作为其方法的核心。目前正在攻读金融硕士学位，Saqib 致力于获得 CFA 牌照，以进一步增进他在这一领域的专业知识。</p>
</div>

2024 年夏季最值得购买的三大生物科技股